XVIPF (Xvivo Perfusion AB) Growth Rank: 9 (As of Jun. 28, 2026) — 13% Above Median


XVIPF Xvivo Perfusion AB XVIPF
87 GF Score
Price $29.00
GF Value $47.23
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Growth Rank?

Xvivo Perfusion AB XVIPF -1.32% 87 Growth Rank is 9 as of Jun. 28, 2026, which is 13% above its 10-year median of 8.00. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Xvivo Perfusion AB has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Xvivo Perfusion AB Growth Rank Related Terms

XVIPF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Growth Rank falls into.


XVIPF
87GF Score
Xvivo Perfusion AB XVIPF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
Xvivo Perfusion AB (XVIPF) has a Growth Rank of 9 as of Jun. 28, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Xvivo Perfusion AB and its competitors. This is 13% above median its historical median of 8.00. Over the past decade, Xvivo Perfusion AB's Growth Rank has ranged from 2.00 to 9.00.
Is Xvivo Perfusion AB's Growth Rank too high?
Xvivo Perfusion AB's current Growth Rank of 9 is 13% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Growth Rank compare to ABT and SYK?
Xvivo Perfusion AB's Growth Rank of 9 can be compared against companies in the Medical Devices & Instruments industry. Historically, Xvivo Perfusion AB's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Growth Rank is 9, which is 13% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current Growth Rank is 9, which is 13% above median its 10-year median of 8.00. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Growth Rank is 9 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Growth Rank: 9 (13% above median its 10-year median of 8.00)
  • GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score

Get the complete analysis for XVIPF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$47.23
GF Value